TNXP Latest Press Releases

-- October 27, 2026 --

Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain Globe Newswire 7:00 AM

-- October 26, 2026 --

Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026 Globe Newswire 7:00 AM

-- October 19, 2026 --

Tonix Pharmaceuticals to Present an Analysis of Phase 3 Data on TONMYA at the IASP 2026 World Congress on Pain Globe Newswire 7:00 AM

-- October 15, 2026 --

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026 Globe Newswire 7:00 AM

-- September 22, 2026 --

Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA Globe Newswire 7:00 AM

-- September 8, 2026 --

Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer Globe Newswire 7:00 AM

-- September 2, 2026 --

Tonix Pharmaceuticals to Participate in Cantor's 2026 Global Healthcare Conference Globe Newswire 7:00 AM

-- August 10, 2026 --

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights Globe Newswire 7:00 AM

-- August 5, 2026 --

Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences Globe Newswire 7:00 AM

-- August 3, 2026 --

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. Globe Newswire 7:00 AM

-- July 27, 2026 --

Tonix Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 10, 2026 Globe Newswire 7:00 AM

-- July 15, 2026 --

Tonix Pharmaceuticals Announces Publication in the Peer-Reviewed Journal of Virology Assessing Virulence of the 2022 Outbreak Strain of Mpox in New Animal Models Globe Newswire 9:05 AM

-- July 13, 2026 --

Tonix Pharmaceuticals Announces Major Managed Medicare Payer Agreement for TONMYA Globe Newswire 7:00 AM

-- June 29, 2026 --

Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) Globe Newswire 7:25 AM

-- June 11, 2026 --

Tonix Pharmaceuticals to Attend BTIG Infectious Disease Day 2026 Globe Newswire 7:00 AM

-- June 8, 2026 --

Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA, Expanding Total Commercial Coverage to ~52 Million U.S. Lives Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes